Anti-Reflection (AR) Coating Meter

Wada, Toshiki; Sato, Yoshitake; Suzuki, Kazuyuki; Aono, Hiroshi; Chen, Din-Guo; Yan, Andrew Yongan; Ono, Yūichi; Takamatsu, Masahiro

doi:10.4271/1999-01-0897

Cited by 5 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Technical document 'Reporting and Evaluation Guidance for Testosterone, Epitestosterone, T/E Ratio and other Endogenous Steroids', TD2004EAAS, currently under revision). [8] Historically, the administration of testosterone was initially identified based on a threshold of the testosterone/epitestosterone ratio of six. Any ratio greater than six was originally considered as an adverse finding.…”

Section: Introductionmentioning

confidence: 99%

Significant increase of salivary testosterone levels after single therapeutic transdermal administration of testosterone: suitability as a potential screening parameter in doping control

Thieme¹,

Rautenberg²,

Grosse³

et al. 2013

Drug Testing and Analysis

View full text Add to dashboard Cite

The legally defensible proof of the abuse of endogenous steroids in sports is currently based on carbon isotope ratio mass spectrometry (IRMS), i.e. a comparison between (13)C/(12)C ratios of diagnostic precursors and metabolites of testosterone. The application of this technique requires a chromatographic baseline separation of respective steroids prior to IRMS detection and hence laborious sample pre-processing of the urinary steroid extracts including clean up by solid-phase extraction and/or liquid chromatography. Consequently, an efficient pre-selection of suspicious control urine samples is essential for appropriate follow up confirmation by IRMS and effective doping control. Two single transdermal administration studies of testosterone (50 mg Testogel® and Testopatch® at 3.8 mg in 16 h, respectively) were conducted and resulting profiles of salivary testosterone and urinary steroid profiles and corresponding carbon isotope ratios were determined. Conventional doping control markers (testosterone/epitestosterone ratio, threshold concentrations of androsterone, etiocholanolone, or androstanediols) did not approach or exceed critical thresholds. In contrast to these moderate variations, the testosterone concentration in oral fluid increased from basal values (30-142 pg/mg) to peak concentrations above 1000 pg/mg. It is likely that this significant increase in oral fluid is due to a pulsatile elevation of free (protein unbound) circulating testosterone after transdermal administration and may be assumed to represent a more diagnostic marker for transdermal testosterone administration.

show abstract

Section: Introductionmentioning

confidence: 99%